688331.SSClinical Trials•prnewswire•
Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren's Syndrome in China
Sentiment:Positive (80)
Summary
YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met the primary endpoint in its Phase III clinical trial for the treatment of primary...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 13, 2025 by prnewswire